Is Your Pharmacist a Salesperson or a Healthcare Provider? Understanding Drug Advertising in Brazil
"Unveiling the hidden truths behind pharmaceutical marketing tactics and their impact on your health decisions in Brazil"
Drug advertising possesses the power to shape societal perspectives, reflect cultural values, and influence health-related behaviors. Pharmaceutical companies wield this powerful tool to communicate with healthcare professionals, including pharmacists, who play a crucial role in dispensing medications and advising patients. However, when the primary goal of drug advertising shifts from providing essential information to driving sales, ethical concerns arise.
In Brazil, the pharmaceutical industry's marketing strategies targeting pharmacists have come under scrutiny. A research article published in the Brazilian Journal of Pharmaceutical Sciences delved into the nature of drug advertising directed at pharmacists in Brazil, questioning whether these ads prioritize information or sales promotion. This article sheds light on the potential conflict between the pharmacist's role as a healthcare provider and the pressure to boost pharmaceutical sales.
This article analyzes the findings of this research, explores the implications of sales-oriented drug advertising, and emphasizes the importance of pharmacists maintaining their role as trusted healthcare advisors. We aim to empower you with the knowledge to navigate the complexities of pharmaceutical marketing and make informed decisions about your health.
The Scale and Scrutiny of Drug Advertising
Pharmaceutical advertising is one of the most heavily scrutinized corners of the marketing world, and regulators keep tightening the rules. The FDA recently announced new regulations for direct-to-consumer (DTC) advertising, requiring pharma companies to include a "Major Statement" in their ads. The industry's footprint is enormous: WHO pharmacy workforce statistics count 4,067,718 pharmacists worldwide in 2017, and the top 10 pharma companies generated $1.845 trillion on the stock exchange in 2018. US drug companies reportedly spend more on advertising than on research and development. Yet effectiveness is not assured, since Kantar's BrandZ data shows pharma brands scoring only around average on "having great advertising," with consumer engagement varying widely by generation.
Blending Traditional and Digital Tactics
Pharmaceutical marketing blends traditional and digital channels rather than choosing between them. Print advertising in medical publications and distributing informative materials like pamphlets and brochures in medical facilities' waiting areas and offices remain effective complements to digital efforts. The ongoing debate between sticking with old-school newspaper ads and flyers versus adopting smarter, digital-first methods continues to shape how pharmacies plan their budgets. Across these channels, the range of tactics runs from Google Ads to detailing and advertising to third parties. A common thread, according to practitioners, is that pharma design succeeds not by escaping limitations but by treating every regulatory constraint as an invitation to communicate more clearly and creatively.
From Vintage Remedy Ads to a $5 Billion TV Category
Pharmaceutical advertising has deep roots, as a glance at vintage drug ads shows—including historical mental health advertisements such as the Zoloft ad and antique health remedy ads from earlier eras. These early campaigns stand in stark contrast to today's media footprint. According to the firm iSpot, pharma TV ad spend reached an estimated $5.15 billion in 2024, accounting for 11.6% of all total linear TV ad spend in the United States. The evolution from print remedy ads to a category with outsized influence over the advertising economy is a recurring theme in industry histories. As one history podcast notes, understanding how pharmaceutical advertising got here is the first step toward deciding what changes to push for going forward.
The Core of the Issue: Advertising Strategies and Their Impact
The research, led by Jussara Calmon Reis de Souza Soares, analyzed a series of drug advertisements published in Brazilian technical journals aimed at pharmacists and other healthcare professionals. The study focused on the content of the messages, critically examining the role attributed to pharmacists and discussing it within the context of pharmaceutical care.
- Emphasis on Sales: The ads predominantly highlighted sales targets and profit margins, overshadowing crucial information about drug interactions, side effects, and appropriate usage.
- Pharmacists as Salesmen: The advertisements often portrayed pharmacists as salesmen rather than healthcare professionals, encouraging them to prioritize sales over patient well-being.
- Promotion of Heavily Advertised Drugs: Pharmacists were encouraged to sell pharmaceutical drugs that were also heavily advertised to medical doctors, potentially leading to over-prescription and inappropriate medication use.
From Persuasion to Patient Empowerment
Recent research suggests pharmaceutical advertising may be shifting from persuasion toward empowerment. In August 2021, DeepIntent surveyed 1,244 U.S. patients and found that pharmaceutical ads can empower patients to take a more active role in researching treatment and medication options. The company's analysis argues that ads aren't just about promoting medication—they spark and inform critical conversations and help make healthcare more accessible. Separately, industry observers report that pharma advertising is moving toward clearer, more transparent communication as companies face growing expectations from regulators and the public. Together, these findings point to a redefinition of the drug advertisement's role in the patient journey.
Therapeutic or Toxic? The Case Against DTC Ads
Critics of direct-to-consumer (DTC) pharmaceutical advertising argue that it has a darker side. A 2011 review in the journal P&T posed the question bluntly: "Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?" Academic commentary has also leveled the criticism that DTC advertising fails to inform consumers about proper medicine use, and researchers note that limited knowledge exists on the role of pharmaceutical advertising from a public health perspective. Regulators have responded by classifying DTC ads into distinct categories, with "product claim" ads explicitly naming a drug, the condition it treats, and making claims about its safety and effectiveness. The ongoing dispute reflects a core tension: advertising designed to inform may also mislead.
When Ads Attack Rivals
Comparative advertising is a well-established, and sometimes litigious, practice in pharma. Academic work models comparative advertising as brands "pushing up" their own brand perception while "pulling down" the brand image of targeted rivals, as seen in a study of TV advertisements for over-the-counter analgesics broadcast between 2001 and 2005. The stakes of these comparisons surfaced publicly when Novo Nordisk sued Eli Lilly over GLP-1 advertising claims, alleging that Lilly's ads compared the highest approved doses of Zepbound and Mounjaro with lower-dose versions of Novo Nordisk's therapies while omitting more recently approved or higher-dose alternatives. Against this backdrop, measures of advertising effectiveness show pharma brands scoring only around average on being distinctive, well-branded, and conveying meaningful difference. The lesson for consumers is that comparative drug ads should be read with a skeptical eye.
Protecting Your Health: What You Can Do
The findings of this research highlight the importance of being a proactive and informed healthcare consumer. Here are some steps you can take to ensure you receive the best possible pharmaceutical care: <ul> <li><b>Ask Questions:</b> Don't hesitate to ask your pharmacist questions about your medications, including their purpose, potential side effects, and interactions with other drugs.</li> <li><b>Seek Independent Information:</b> Consult reliable sources of health information, such as your doctor, reputable websites, and patient advocacy groups, to learn more about your medications.</li> <li><b>Be Aware of Sales Tactics:</b> Recognize that pharmacists may be influenced by sales incentives. Prioritize your health needs over any potential sales pressure.</li> <li><b>Report Concerns:</b> If you have concerns about the advice or treatment you receive from a pharmacist, report them to the appropriate regulatory authorities.</li> </ul> By empowering yourself with knowledge and taking an active role in your healthcare decisions, you can ensure that your pharmacist acts as a trusted healthcare advisor, prioritizing your well-being over sales targets. Remember, your health is your most valuable asset. Stay informed, ask questions, and demand the best possible care.
A Twenty-Year Divide Among Experts
Expert opinion on direct-to-consumer (DTC) pharmaceutical advertising has been split for two decades. A 2004 study in the Archives of Internal Medicine examined physician and public opinion and the potential effects of DTC advertising on the physician-patient relationship. Critics of the status quo argue that the FDA should reduce the risks of irresponsible DTC advertising and have proposed specific ways to do so. The financial stakes behind these debates are enormous, with the pharmaceutical industry on track to reach $1.12 trillion by 2022 and advertising budgets at all-time highs—funding that, some commentators argue, gives drugmakers leverage over what appears in the media. Where a pharmacist sits in this system, then, is shaped by pressures that go well beyond the counter.
Digital Growth Amid Slow FDA Approvals
Digital is where the growth in pharma advertising is headed. Pharma digital advertising was projected to hit $10 billion in 2020, driven in part by requirements for multi-channel strategies that are distinct to the pharmaceutical space. Market forecasts point in the same direction, with the Singapore big data pharmaceutical advertising market estimated at $6.2 billion in 2024 and projected to reach $15 billion by 2033. Adoption, however, is not instant: pharma has historically been slow to embrace new advertising technologies, largely because of the slow-moving FDA approval process for advertising. Even so, industry trackers say a growing set of techniques is gaining popularity in healthcare advertising, signaling accelerating change ahead.
Measuring Impact While Staying Compliant
Pharmaceutical advertisers face systemic challenges that go beyond creativity. Measuring ROI is a central concern, with campaigns judged against key metrics and KPIs for evaluating performance. At the same time, companies must navigate regulations carefully to maximize advertising impact while maintaining legal compliance, a tension that market analyses such as those covering the Taiwan direct-to-consumer pharmaceutical advertising market describe as prioritizing cost control and efficiency. Newer capabilities add complexity: self-serve NPI targeting introduced to the pharmaceutical space comes with a set of implementation considerations that advertisers must weigh before adoption. For pharmacies deciding whether the pharmacist behind the counter is more salesperson or provider, these structural pressures help explain why advertising has become so pervasive.
Advertising That Follows Patient Data
Behind the spending totals is a data-driven shift in how pharma advertising actually reaches people. The real reason drug companies are investing more in advertising, according to industry analyses, is the growing sophistication of real-world data (RWD) for understanding campaign impact and optimizing it. AI and RWD adoption is accelerating campaign precision, allowing pharma brands to target patients by diagnosis code, treatment history, and behavioral health signals within HIPAA-compliant environments. Real-world evidence—information gathered during routine clinical practice from health records, patient registries, and even social media—is increasingly central to advertising, including in markets like Portugal. The result is advertising that can follow patients by their health data, which raises questions about what that means for the pharmacist's role as an independent advisor.